Arinditia Triasti Putri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arinditia Triasti Putri has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Awalia Awalia
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Division of Rheumatology, Surabaya, Indonesia
1 shared publication- Betty Rachma
Internal Medicine Specialist Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
1 shared publication - Cahyo Wibisono Nugroho
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Division of Rheumatology, Surabaya, Indonesia
1 shared publication - Henry Sutanto
Internal Medicine Specialist Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
1 shared publication - Lita Diah Rahmawati
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Division of Rheumatology, Surabaya, Indonesia
1 shared publication - Yuliasih Yuliasih
Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Division of Rheumatology, Surabaya, Indonesia
1 shared publication
Latest Publications
- Open Access
- 8 December 2025
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 52 (1) , 72
A narrative review of bone disease in spondyloarthropathy: molecular mechanisms and emerging advances
Introduction: Spondyloarthropathies (SpA) are chronic inflammatory disorders characterized by the paradoxical coexistence of bone loss and pathological new bone formation, leading to syndesmophytes, ankylosis, erosions, and osteoporosis. These skeletal changes severely impair mobility and heighten fracture risk. Methodology: This narrative review was conducted by non-systematically searching PubMed, Scopus, Google Scholar, and Web of Science databases up to September 2025 for studies addressing the molecular mechanisms, imaging correlates, and therapeutic strategies in bone disease of SpA. Reference lists were manually screened to include additional relevant literature. Discussion: Evidence highlights the pathogenic role of cytokines such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 in orchestrating crosstalk between immune and bone cells. Dysregulation of the Wnt/β-catenin pathway and the receptor activator of nuclear factor-κB (RANK)–RANK ligand (RANKL)–osteoprotegerin (OPG) axis underpins the imbalance between osteoclast-mediated resorption and osteoblast-driven ossification. Imaging modalities, including MRI and high-resolution quantitative CT, have advanced early detection and monitoring of structural lesions. Biologic and targeted synthetic agents, notably TNF inhibitors, IL-17 antagonists, and Janus kinase inhibitors, effectively reduce inflammation and bone loss but show limited impact on syndesmophyte progression. Future directions: Integration of molecular biomarkers, multi-omics profiling, and advanced imaging may enable precision medicine approaches. Therapeutic strategies directly targeting Wnt and BMP signaling represent promising avenues to prevent pathological ossification. Conclusion: Bone disease in SpA arises from intertwined inflammatory, genetic, and mechanical mechanisms. Despite therapeutic advances, structural progression remains unresolved. Future research should focus on interventions that couple anti-inflammatory activity with modulation of bone remodeling to prevent fractures and ankylosis.
- 8 December 2025
- Published by Springer Nature in Egyptian Rheumatology and Rehabilitation
- Vol. 52 (1) , 72
Open AccessA narrative review of bone disease in spondyloarthropathy: molecular mechanisms and emerging advances
Introduction: Spondyloarthropathies (SpA) are chronic inflammatory disorders characterized by the paradoxical coexistence of bone loss and pathological new bone formation, leading to syndesmophytes, ankylosis, erosions, and osteoporosis. These skeletal changes severely impair mobility and heighten fracture risk. Methodology: This narrative review was conducted by non-systematically searching PubMed, Scopus, Google Scholar, and Web of Science databases up to September 2025 for studies addressing the molecular mechanisms, imaging correlates, and therapeutic strategies in bone disease of SpA. Reference lists were manually screened to include additional relevant literature. Discussion: Evidence highlights the pathogenic role of cytokines such as tumor necrosis factor (TNF), interleukin (IL)-17, and IL-23 in orchestrating crosstalk between immune and bone cells. Dysregulation of the Wnt/β-catenin pathway and the receptor activator of nuclear factor-κB (RANK)–RANK ligand (RANKL)–osteoprotegerin (OPG) axis underpins the imbalance between osteoclast-mediated resorption and osteoblast-driven ossification. Imaging modalities, including MRI and high-resolution quantitative CT, have advanced early detection and monitoring of structural lesions. Biologic and targeted synthetic agents, notably TNF inhibitors, IL-17 antagonists, and Janus kinase inhibitors, effectively reduce inflammation and bone loss but show limited impact on syndesmophyte progression. Future directions: Integration of molecular biomarkers, multi-omics profiling, and advanced imaging may enable precision medicine approaches. Therapeutic strategies directly targeting Wnt and BMP signaling represent promising avenues to prevent pathological ossification. Conclusion: Bone disease in SpA arises from intertwined inflammatory, genetic, and mechanical mechanisms. Despite therapeutic advances, structural progression remains unresolved. Future research should focus on interventions that couple anti-inflammatory activity with modulation of bone remodeling to prevent fractures and ankylosis.